Blum Robert I 4

What Happened

Robert I. Blum, President, CEO and Director of Cytokinetics (CYTK), disposed of 7,500 shares in an open-market sale on May 27, 2026. The shares traded at $77.21 each for total proceeds of approximately $579,075. This was a sale (transaction code S), not a purchase or option exercise.

Key Details

• Transaction date and price: 2026-05-27 — 7,500 shares @ $77.21 per share; proceeds ≈ $579,075.
• Transaction type: Open-market sale (Form 4 code S).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 — shares held by The Bridget Blum 2003 Irrevocable Trust; F2 — shares held by The Brittany Blum 2003 Irrevocable Trust.
• Filing timeliness: Report filed 2026-05-28 for a 2026-05-27 transaction (filed the next day; appears timely).

Context

This report documents an outright sale of company stock by the CEO. Sales by insiders are common and can reflect routine liquidity, tax planning or other personal reasons; they do not necessarily indicate a change in management’s view of the company. Purchases are generally viewed as a stronger signal of insider confidence than routine sales.